European Society of Hypertension position paper on renal denervation 2021
Schmieder R, Mahfoud F, Mancia G, Azizi M, Boehm M, Dimitriadis K, Kario K, Kroon AA, Lobo MD, Ott C, Pathak A, Persu A, Scalise F, Schlaich M, Kreutz R, Tsioufis C (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 39
Pages Range: 1733-1741
Journal Issue: 9
DOI: 10.1097/HJH.0000000000002933
Abstract
This ESH Position Paper 2021 with updated proposed recommendations was deemed necessary after the publication of a set of new pivotal sham-controlled randomized clinical trials (RCTs), which provided important information about the efficacy and safety of endovascular device-based renal denervation (RDN) for hypertension treatment. RDN is effective in reducing or interrupting the sympathetic signals to the kidneys and decreasing whole body sympathetic activity. Five independent, fully completed, sham-controlled RCTs provide conclusive evidence that RDN lowers ambulatory and office blood pressure (BP) to a significantly greater extent than sham treatment. BP-lowering efficacy is evident both in patients with and without concomitant antihypertensive medication. The average decrease of 10mmHg in office BP is estimated to lower the incidence of cardiovascular events by 25-30%, based on meta-analyses of RCTs using pharmacological treatment. Neither peri-procedural, nor short-term or long-term adverse events or safety signals (available up to 3 years) have been observed. Implementing RDN as an innovative third option in the armamentarium of antihypertensive treatment requires a structured process that ensures the appropriate performance of the endovascular RDN procedure and adequate selection of hypertensive patients. The latter should also incorporate patients' perspective and preference that needs to be respected in a shared decision-making process.
Authors with CRIS profile
Involved external institutions
Universität des Saarlandes (UdS)
Germany (DE)
University of Western Australia (UWA)
Australia (AU)
National and Kapodistrian University of Athens
Greece (GR)
University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB
Italy (IT)
Jichi Medical University / 自治医科大学
Japan (JP)
Paracelsus Medizinische Privatuniversität
Austria (AT)
Charité - Universitätsmedizin Berlin
Germany (DE)
National Center for Scientific Research / Centre national de la recherche scientifique (CNRS)
France (FR)
Maastricht University
Netherlands (NL)
Queen Mary University of London
United Kingdom (GB)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Université Catholique de Louvain (UCL)
Belgium (BE)
Germany (DE)
University of Western Australia (UWA)
Australia (AU)
National and Kapodistrian University of Athens
Greece (GR)
University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB
Italy (IT)
Jichi Medical University / 自治医科大学
Japan (JP)
Paracelsus Medizinische Privatuniversität
Austria (AT)
Charité - Universitätsmedizin Berlin
Germany (DE)
National Center for Scientific Research / Centre national de la recherche scientifique (CNRS)
France (FR)
Maastricht University
Netherlands (NL)
Queen Mary University of London
United Kingdom (GB)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Université Catholique de Louvain (UCL)
Belgium (BE)
How to cite
APA:
Schmieder, R., Mahfoud, F., Mancia, G., Azizi, M., Boehm, M., Dimitriadis, K.,... Tsioufis, C. (2021). European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 39(9), 1733-1741. https://doi.org/10.1097/HJH.0000000000002933
MLA:
Schmieder, Roland, et al. "European Society of Hypertension position paper on renal denervation 2021." Journal of Hypertension 39.9 (2021): 1733-1741.
BibTeX: Download